Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities.

[1]  C. Gross,et al.  The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications. , 2013, International journal of radiation oncology, biology, physics.

[2]  D. Jarrar,et al.  Multimodality approach to management of stage III non-small cell lung cancer. , 2013, Surgical oncology clinics of North America.

[3]  A. Zietman,et al.  Clinical Investigation : The Profession Proton Beam Therapy and Accountable Care : The Challenges Ahead , 2013 .

[4]  S. Hahn,et al.  The body of evidence for advanced technology in radiation oncology. , 2013, Journal of the National Cancer Institute.

[5]  T. Buchholz,et al.  Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Joe Y. Chang,et al.  Clinical Investigation : Thoracic Cancer Comparative Effectiveness of 5 Treatment Strategies for Early-Stage Non-Small Cell Lung Cancer in the Elderly , 2012 .

[7]  S. Senan,et al.  Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  T. Stinchcombe,et al.  Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. , 2012, The oncologist.

[9]  P. Lambin,et al.  Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study. , 2011, European journal of cancer.

[10]  J. Welsh,et al.  Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. , 2011, Medical Dosimetry.

[11]  S. Senan,et al.  Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  D. Schrag,et al.  Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Jagsi,et al.  Adoption of intensity-modulated radiation therapy for breast cancer in the United States. , 2011, Journal of the National Cancer Institute.

[14]  J. Iglehart.  The ACO regulations--some answers, more questions. , 2011, The New England journal of medicine.

[15]  S. Lipsitz,et al.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Buchholz,et al.  Brachytherapy for accelerated partial-breast irradiation: a rapidly emerging technology in breast cancer care. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Steven M Lieberman,et al.  Building regulatory and operational flexibility into accountable care organizations and 'shared savings'. , 2011, Health affairs.

[18]  Jose Belderbos,et al.  Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Mayles.  Survey of the availability and use of advanced radiotherapy technology in the UK. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[20]  M. Edelman,et al.  Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Gross,et al.  Integrated prostate cancer centers and over-utilization of IMRT: a close look at fee-for-service medicine in radiation oncology. , 2010, International journal of radiation oncology, biology, physics.

[22]  Radhe Mohan,et al.  Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[23]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[24]  Thomas J. Smith,et al.  American Society of Clinical Oncology guidance statement: the cost of cancer care. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[26]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Andrew Jackson,et al.  Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  A. Adjei,et al.  Small cell lung cancer. , 2008, Mayo Clinic proceedings.

[29]  Radhe Mohan,et al.  Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[30]  Radhe Mohan,et al.  Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[31]  Thomas Guerrero,et al.  Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[32]  Di Yan,et al.  Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. , 2003, International journal of radiation oncology, biology, physics.

[33]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[34]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[35]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[36]  Joel E. Tepper,et al.  Clinical Radiation Oncology , 2000 .

[37]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[38]  E. Shaw,et al.  Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[40]  J. Sunshine,et al.  Consequences of physicians' ownership of health care facilities--joint ventures in radiation therapy. , 1992, The New England journal of medicine.

[41]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[42]  J. Crowley,et al.  Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[44]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .